| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20064211 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20064150 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS44027967 | HTLV-1 | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS44049811 | HTLV-1 | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS44035846 | HTLV-1 | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2C |
|---|---|
| DrugBank ID | DB00714 |
| Drug Name | Apomorphine |
| Target ID | BE0000533 |
| UniProt ID | P28335 |
| Regulation Type | agonist |
| PubMed IDs | 18691132; 15037665 |
| Citations | Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.@@LeWitt PA: Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004 Mar 23;62(6 Suppl 4):S8-11. doi: 10.1212/wnl.62.6_suppl_4.s8. |
| Groups | Approved; Investigational |
| Direct Classification | Aporphines |
| SMILES | [H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23 |
| Pathways | |
| PharmGKB | PA164781163 |
| ChEMBL | CHEMBL53 |
